MTOR and liver cancer: Strikingly, sorafenib accelerates hepcidin gene contents in Huh7 liver cancer cells when combined with numerous other kinase repressors, consisting of phosphoinositide 3-kinase (PI3K), the mechanistic target of rapamycin (mTOR), Ras/mitogen-activated protein kinase (MAPK), along with AMP-activated protein kinase (AMPK) cascade inhibitors (45).